Immune-based therapies for hepatocellular carcinoma

被引：181

作者：

Pinato, David J. ^{[1
]}

Guerra, Nadia ^{[2
]}

Fessas, Petros ^{[1
]}

Murphy, Ravindhi ^{[1
]}

Mineo, Takashi ^{[3
]}

Mauri, Francesco A. ^{[1
]}

Mukherjee, Sujit K. ^{[4
]}

Thursz, Mark ^{[4
]}

Wong, Ching Ngar ^{[1
]}

Sharma, Rohini ^{[1
]}

Rimassa, Lorenza ^{[5
,6
]}

机构：

[1] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England

[2] Imperial Coll London, Dept Life Sci, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England

[3] Tokyo Med & Dent Univ, Tokyo, Japan

[4] Imperial Coll London, Dept Metab Digest & Reprod, St Marys Hosp, Praed St, London, England

[5] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Haematol Unit, Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy

[6] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, I-20090 Milan, Italy

来源：

ONCOGENE | 2020年 / 39卷 / 18期

基金：

英国惠康基金;

关键词：

REGULATORY T-CELLS; GROWTH-FACTOR-BETA; CHRONIC HEPATITIS-B; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR MICROENVIRONMENT; DOUBLE-BLIND; PHASE-III; TGF-BETA; ADOPTIVE IMMUNOTHERAPY;

D O I：

10.1038/s41388-020-1249-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

引用

页码：3620 / 3637

页数：18

共 50 条

[31] Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
Hattinger, Claudia Maria
Salaroglio, Iris Chiara
Fantoni, Leonardo
Godel, Martina
Casotti, Chiara
Kopecka, Joanna
Scotlandi, Katia
Ibrahim, Toni
Riganti, Chiara
Serra, Massimo
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
[32] Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Jessica A. Wilcox
Adrienne A. Boire
CNS Drugs, 2023, 37 : 45 - 67
[33] Treatment duration with immune-based therapies in Cancer: an enigma
Bantia, Shanta
Choradia, Nirmal
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[34] Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Wilcox, Jessica A.
Boire, Adrienne A.
CNS DRUGS, 2023, 37 (01) : 45 - 67
[35] Oncologic Emergencies: Immune-Based Cancer Therapies and Complications
Long, Brit
Brem, Elizabeth
Koyfman, Alex
WESTERN JOURNAL OF EMERGENCY MEDICINE, 2020, 21 (03) : 566 - 580
[36] Immune-based therapies for metastatic prostate cancer: an update
Hossain, Md Kamal
Nahar, Kamrun
Donkor, Osaana
Apostolopoulos, Vasso
IMMUNOTHERAPY, 2018, 10 (04) : 283 - 298
[37] Immune-based therapies: an adjunct to antiretroviral treatment.
Jacobson J.M.
Current HIV/AIDS Reports, 2005, 2 (2) : 90 - 97
[38] CD5 as a Target for Immune-Based Therapies
Consuegra-Fernandez, Marta
Aranda, Fernando
Simoes, Ines
Orta, Marc
Sarukhan, Adelaida
Lozano, Francisco
CRITICAL REVIEWS IN IMMUNOLOGY, 2015, 35 (02) : 85 - 115
[39] Progress in immune-based therapies for type 1 diabetes
von Herrath, M.
Peakman, M.
Roep, B.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 172 (02): : 186 - 202
[40] The role of CXCL8 and CCNB1 in predicting hepatocellular carcinoma in the context of cirrhosis: implications for early detection and immune-based therapies
Qingyuan Sun
Ran An
Jingxin Li
Chuanyong Liu
Menggeer Wang
Chao Wang
Yanqing Wang
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 11471 - 11489

← 1 2 3 4 5 →